170 related articles for article (PubMed ID: 22421160)
1. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.
Belleudi F; Marra E; Mazzetta F; Fattore L; Giovagnoli MR; Mancini R; Aurisicchio L; Torrisi MR; Ciliberto G
Cell Cycle; 2012 Apr; 11(7):1455-67. PubMed ID: 22421160
[TBL] [Abstract][Full Text] [Related]
2. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
3. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
4. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
Gordon-Thomson C; Jones J; Mason RS; Moore GP
Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
[TBL] [Abstract][Full Text] [Related]
5. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
6. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
8. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
9. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.
Schoeberl B; Pace EA; Fitzgerald JB; Harms BD; Xu L; Nie L; Linggi B; Kalra A; Paragas V; Bukhalid R; Grantcharova V; Kohli N; West KA; Leszczyniecka M; Feldhaus MJ; Kudla AJ; Nielsen UB
Sci Signal; 2009 Jun; 2(77):ra31. PubMed ID: 19567914
[TBL] [Abstract][Full Text] [Related]
10. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.
D'Souza JW; Reddy S; Goldsmith LE; Shchaveleva I; Marks JD; Litwin S; Robinson MK
PLoS One; 2014; 9(11):e112376. PubMed ID: 25386657
[TBL] [Abstract][Full Text] [Related]
11. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
12. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
13. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
14. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B
Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735
[TBL] [Abstract][Full Text] [Related]
15. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
16. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
17. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
19. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
20. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
Redlich N; Robinson AM; Nickel KP; Stein AP; Wheeler DL; Adkins DR; Uppaluri R; Kimple RJ; Van Tine BA; Michel LS
Cell Death Dis; 2018 Jan; 9(1):5. PubMed ID: 29305574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]